Efecto de la suplementación con vitamina E natural en el agua de bebida sobre el nivel sérico de tocoferol y actividad antioxidante en lechones tras el destete

En el presente trabajo se estudió la influencia de la suplementación de vitamina E natural (D-α - tocoferol) en el agua de bebida administrada simultáneamente con la forma sintética en pienso a cerdas durante el periodo de lactación y/o a los lechones tras el destete, sobre la concentración de α-tocoferol en el suero del lechón así como su poder antioxidante. Los lechones suplementados con vitamina E natural en el agua de bebida, que nacieron de las madres que se suplementaron con la misma forma de vitamina E (S-Cerda-Lechón) tuvieron la más alta concentración de α-tocoferol a los 5 días post-destete, mientras que la más baja concentración de tocoferol fue encontrado en el grupo que consumió la forma sintética (α- tocoferol acetato) y que nacieron de las madres que consumieron esta misma forma de vitamina E (Control). El FRAP del suero se afectó de forma significativa por la suplementación con vitamina E natural de los lechones (P=0.037). Los efectos observados fueron debidos principalmente a la suplementación de los lechones

Eumycetoma caused by Diaporthe phaseolorum (Phomopsis phaseoli): a case report and a mini-review of Diaporthe/Phomopsis spp invasive infections in humans

AbstractDiaporthe phaseolorum (syn. Phomopsis phaseoli) is a frequent fungal parasite of plants, present on all continents around the world. It has rarely been involved in human diseases. We report a case of eumycetoma with osteomyelitis of the forefoot caused by this fungus and diagnosed by molecular biology. The patient had positive HTLV-1 serology and was a farmer from French Guiana who walked barefoot. He was successfully treated with long-term oral itraconazole (400 mg/day). A review of the literature underlines the essential roles of plants and host immunosuppression in this infection and the favourable outcome with a triazole antifungal treatment

Quantification of γ- and α-tocopherol isomers in combination with pattern recognition model as a tool for differentiating dry-cured shoulders of Iberian pigs raised on different feeding systems

BACKGROUND Quantification of γ- and α-tocopherol in dry-cured shoulders of Iberian pigs was evaluated as a tool for differentiating feeding backgrounds or regimens. Samples (n = 115) were obtained over two different seasons from the four categories of pigs described in the Industry Quality Policy, i.e. pigs fed in free-range conditions (FREE-RANGE), pigs fed in free-range conditions and provided feed supplements (FREE-FEED), pigs fed outdoors with feed and with access to grass (FEED-OUT) and pigs fed in intensive conditions with feed (FEED). Linear discriminant functions were calculated and validated. RESULTS The validation results showed that 20% of the muscle samples were not correctly classified into the four feeding categories, giving an 80% success rate. The FEED group had the lowest proportion of errors, with 100% of samples correctly classified. For the FREE-RANGE group, 87% of samples were assigned to the correct feeding system by cross-validation; however, 13% were considered as FREE-FEED. A higher rate of correct classification can be obtained when using three categories or by calculating the weight gain in free-range conditions using regression equations. CONCLUSION Taking into account the high variability of the samples and the high success in classification, these results are of interest and may be applied in practical situations. © 2014 Society of Chemical Industry

Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis

Introduction: Apremilast is a drug recently developed for psoriasis. Few data are available on its use in the elderly. We evaluated the tolerance and effectiveness of apremilast used in daily practice for psoriasis treatment in older patients. Methods: We performed a multicenter, retrospective study involving patients aged ≥ 65 years who had received apremilast as a psoriasis treatment. Demographic data and details regarding psoriasis and adverse events (AEs) were collected from patient medical records. Results: 135 patients were included (mean age: 73.5 years). Treatment was stopped in 74 patients (54.8%) for AEs (n = 43, 56.6%), primary failures (n = 18, 23.4%), and relapses (n = 7, 9.2%). When patients were stratified by age at treatment initiation, the main cause of discontinuation in patients ≥ 75 years was AEs, whereas in patients aged 65–74 years it was primary failures (28.3%). Sixty-one patients reported AEs, mainly digestive (n = 49). Regarding effectiveness, 45.2% of patients reached PGA 0/1 between 3 and 6 months after treatment initiation. One-year apremilast continuation rates were better in the 65–74 and 75–84 years subgroups than in the > 85 years subgroup (p = 0.01). Conclusion: Apremilast seems to be an effective and safe therapeutic option for psoriasis in the elderly. The main AEs reported by patients did not seem to differ from those reported previously in younger populations. However, AEs were more frequent in patients > 75 years old leading to more frequent discontinuation of apremilast compared with younger patients, suggesting a higher level of vigilance is needed in the elderly

Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis

Anti-interleukin-17 agents have recently been develo-ped for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practi-ce. A multicentre, retrospective study was performed, involving psoriatic patients aged ≥65 years who had received an anti-interleukin-17 agent, including se-cukinumab, ixekizumab or brodalumab. A total of 114 patients were included: 72 received secukinumab, 35 ixekizumab, and 7 brodalumab. Treatment was stop-ped in 32 patients (28.9%), because of relapses in 14 patients (41.2%), primary failures in 11 patients (32.4%), or adverse events in 7 patients (20.6%). The 3 most frequently reported adverse events were injec-tion site reactions (n = 4), oral candidiasis (n = 3), and influenza-like illness (n = 3). Regarding effectiveness, 80 patients (70%) reached a Physician Global Assessment score of 0/1, 6 months after treatment initiation. In conclusion, anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in patients aged ≥ 65 years